# A Multi-Center, Prospective, Observational Study of Patients Being Treated With ORGOVYX

> **NCT05467176** · — · ACTIVE_NOT_RECRUITING · sponsor: **Sumitomo Pharma America, Inc.** · enrollment: 999 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Relugolix

## Key facts

- **NCT ID:** NCT05467176
- **Lead sponsor:** Sumitomo Pharma America, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-10-04
- **Primary completion:** 2026-06-30
- **Final completion:** 2026-07-30
- **Target enrollment:** 999 (ACTUAL)
- **Last updated:** 2026-04-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05467176

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05467176, "A Multi-Center, Prospective, Observational Study of Patients Being Treated With ORGOVYX". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05467176. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*